“Methylene Bridge” to 5-HT3 Receptor Antagonists: Conformationally Constrained Phenylguanidines
摘要:
Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT3 receptor antagonists. We examined the structure activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT3 receptor antagonist.
Studies on the Synthesis of Benzolactam Rings. II. Synthesis of 1,4-Dihydro-3(2H)-iaoquinolinone Derivatives
作者:Yasuko Kamochi、Yasuo Watanabe
DOI:10.3987/r-1987-09-2385
日期:——
“Methylene Bridge” to 5-HT<sub>3</sub> Receptor Antagonists: Conformationally Constrained Phenylguanidines
作者:Ahmed S. Abdelkhalek、Genevieve S. Alley、Osama I. Alwassil、Shailesh Khatri、Philip D. Mosier、Heather L. Nyce、Michael M. White、Marvin K. Schulte、Małgorzata Dukat
DOI:10.1021/acschemneuro.8b00431
日期:2019.3.20
Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT3 receptor antagonists. We examined the structure activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT3 receptor antagonist.